Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02993159
Recruitment Status : Recruiting
First Posted : December 15, 2016
Last Update Posted : December 21, 2020
Sponsor:
Collaborators:
National Cancer Institute (NCI)
BHR Pharma, LLC
Information provided by (Responsible Party):
Northwestern University

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 15, 2022
Estimated Study Completion Date : July 15, 2023